知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

3391 条记录 (耗时 0.04 秒)

    MULTIPLE VISCOSITY OIL-IN-WATER COMPOSITION USEFUL AS AN INJECTABLE FILLER AND A SCAFFOLD FOR COLLAGEN GROWTH
    44.
    发明公开
    MULTIPLE VISCOSITY OIL-IN-WATER COMPOSITION USEFUL AS AN INJECTABLE FILLER AND A SCAFFOLD FOR COLLAGEN GROWTH 审中-公开

    公开(公告)号：US20230414828A1

    公开(公告)日：2023-12-28

    申请号：US18037223

    申请日：2022-01-12

    申请人： LORIA PHARMACEUTICAL, LLC

    发明人： Victor LORIA

    IPC分类号： A61L27/18 ,  A61L27/50

    CPC分类号： A61L27/18 ,  A61L27/50 ,  A61L2400/06 ,  A61L2430/34

    摘要： A filler composition which is a pharmaceutically acceptable oil-in-water emulsion including 1-80 vol. % of a first silicone oil having a first viscosity; 15-98 vol. % of water, 1-3 wt. % of a transport medium; 0.05-10 vol. % of a surfactant; and optionally a second silicone oil having a second viscosity lower than the first. The second silicone oil is provided at 1-80 vol. % when the first viscosity is 30,000 cSt or less, or 0-80 vol. % when the first viscosity is greater than 30,000 cSt. At least one of the first silicone oil and the second silicone oil is dispersed in water as droplets having an average diameter of less than 30 microns. The transport medium is sufficiently biodegradable when implanted intradermally or subcutaneously in a human to provide a temporary scaffold for collagen growth between the droplets. A method of making the filler composition and a soft tissue augmentation method are also disclosed.

    Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
    46.
    发明授权
    Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices 有权

    公开(公告)号：US11826485B2

    公开(公告)日：2023-11-28

    申请号：US17238473

    申请日：2021-04-23

    申请人： HyperBranch Medical Technology, Inc.

    发明人： Kenneth E. Stockman ,  Michael A. Carnahan ,  Keith R. D'Alessio ,  Mark W. Grinstaff

    IPC分类号： A61K31/74 ,  A61L26/00 ,  A61K31/785 ,  A61K31/787 ,  A61L27/18 ,  A61L24/04 ,  A61L24/00 ,  A61L27/26 ,  A61L27/52 ,  A61L27/56 ,  A61B17/00 ,  A61K51/12

    CPC分类号： A61L26/0019 ,  A61K31/785 ,  A61K31/787 ,  A61L24/0031 ,  A61L24/0036 ,  A61L24/043 ,  A61L24/046 ,  A61L26/008 ,  A61L26/0052 ,  A61L26/0085 ,  A61L27/18 ,  A61L27/26 ,  A61L27/52 ,  A61L27/56 ,  A61B2017/0065 ,  A61B2017/00951 ,  A61K51/1279 ,  A61L24/00 ,  A61L24/046 ,  C08L79/02 ,  A61L27/18 ,  C08L79/02

    摘要： One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed with a second polymer, such as a polyethylene glycol containing nucleophilic groups. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing electrophilic groups with a cross-linking reagent containing nucleophilic groups. In certain instances, the electrophilic groups on the polyalkyleneimine are activated esters, such as N-hydroxy succinimide ester. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing photopolymerizable groups with ultraviolet or visible light. Compositions used to seal the wound which contain PEI or a derivative of PEI are found to adhere tightly to the tissue. Other aspects of the present invention relate to methods of filling a void of a patient or adhering tissue. In certain instances, the methods use a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Another aspect of the present invention relates to a polymeric composition formed by exposing a polyalkyleneimine to an activated polyalkylene glycol. In certain instances, the composition is attached to mammalian tissue.

    INJECTABLE CUSHIONING HYDROGELS
    48.
    发明公开
    INJECTABLE CUSHIONING HYDROGELS 审中-公开

    公开(公告)号：US20230355843A1

    公开(公告)日：2023-11-09

    申请号：US18225051

    申请日：2023-07-21

    申请人： SUPRA B B.V. ,  ACADEMISCH MEDISCH CENTRUM

    发明人： Anton Willem BOSMAN ,  Theodoor Henri SMIT ,  Gino Matheus Melanie Johannes KERKHOFFS ,  Tobias STORNEBRINK

    IPC分类号： A61L27/52 ,  A61L27/54 ,  A61L27/18

    CPC分类号： A61L27/52 ,  A61L27/54 ,  A61L27/18 ,  A61L2430/06 ,  A61L2400/06 ,  A61L2430/38

    摘要： The invention relates to a kit of parts, consisting of compositions (C1) and (C2) in separate containers, for use in the treatment or prevention of osteoarthritis in a vertebrate, wherein: (a) composition (C1) is a liquid hydrogel formulation comprising a polymer gellant with chemically cross-linkable groups; (b) composition (C2) is an aqueous auxiliary formulation comprising either one or more dissolved cross-linkers Z having two or more reactive groups that can chemically cross-link the polymer gellant by forming covalent bonds; or comprising one or more dissolved compounds Y, selected from the group consisting of oxidant, oxidase, peroxidase and combinations thereof, that initiate or mediate chemical cross-linking of the polymer gellant; wherein said treatment comprises combining compositions (C1) and (C2) to form a liquid hydrogel composition (C3) and administering said liquid hydrogel composition (C3) to the synovial fluid or to the cavity of a synovial joint of the vertebrate, to form a cross-linked hydrogel (C4) in the synovial joint of the vertebrate; or wherein said treatment comprises in a first step administering one of the compositions (C1) or (C2) to the synovial fluid or to the cavity of a synovial joint of the vertebrate and in a second step administering the other of the compositions (C1) or (C2), to form a liquid hydrogel composition (C3) in the synovial joint of the vertebrate that reacts to a cross-linked hydrogel (C4).